Inside the New Strategic Partnership Aiming to Finally Deliver Drugs Past the Blood-Brain Barrier

The blood-brain barrier (BBB) is one of the most stubborn problems in medicine. It protects the brain from harmful substances in the blood, but it also blocks 98% of potential therapeutic drugs. This leaves promising scientific targets for Alzheimer's, Parkinson's, brain cancer, and other neurological conditions stuck in the lab. A new UK partnership aims to change that.

On 2 June 2026, Deep Science Ventures (DSV), a deeptech venture creator, and Medicines Discovery Catapult (MDC), a national life sciences service, announced a strategic collaboration focused squarely on this bottleneck .

Why the Blood-Brain Barrier Remains a Critical Bottleneck

The challenge is not finding what to target. Recent scientific advances have identified a growing number of therapeutic targets for devastating neurological conditions and brain cancers. The problem has always been delivery: getting a drug to cross the tightly packed endothelial cells that line the brain's blood vessels and reach the central nervous system (CNS) in a meaningful concentration without causing toxicity .

This delivery bottleneck means many potentially transformative therapies stall before they ever reach a patient. The MDC and DSV partnership is designed to break that logjam by creating new ventures that specifically tackle this single, high-impact problem.

How the Partnership Works

The collaboration between DSV and MDC takes a venture-creation approach rather than a single research project model. They plan to explore and develop novel technologies specifically for delivering medicines across the BBB and into the CNS. Crucially, the initiative does not stop at research—it is structured to support the actual formation and launch of new biotech companies focused on brain-targeted drug delivery .

This follows DSV's broader model of combining existing scientific knowledge with entrepreneurial scientists to found high-impact startups . MDC, for its part, brings industrial medicines discovery expertise, state-of-the-art laboratories, and a proven model for de-risking early-stage discovery projects and giving them a direct line of sight to the clinic .

The Players: A Venture Creator and a National Drug Discovery Engine

Deep Science Ventures is a London-based venture creator that builds science-driven companies across five sectors, one of which is Pharma. Its curative therapeutics division focuses explicitly on creating ventures to cure diseases using emerging combinatorial techniques . DSV has a track record of working with UK catapults; in 2021, it partnered with the Cell and Gene Therapy Catapult on a similar model to generate innovative approaches within the advanced therapy medicinal products (ATMP) industry .

Medicines Discovery Catapult is a national life sciences service with a mandate to transform UK science into better treatments through strategic partnerships . It functions as an industrial-scale drug discovery engine for entrepreneurs and early-stage companies. In late 2025, MDC was also named an Innovate UK Knowledge Transfer Partnership Knowledge Base, formalizing its role in helping life science businesses validate innovations and accelerate products toward patients .

The combination pairs DSV's methodical venture-building machine with MDC's translational infrastructure and clinical de-risking capabilities.

What It Means for Neurological and Brain Cancer Treatments

The partnership acknowledges a simple reality: scientific discovery has outpaced translational delivery technology. By framing the entire collaboration around the BBB problem, DSV and MDC are betting that a dedicated, venture-led approach can create breakthroughs where broader pharmaceutical R&D has struggled.

Neither organization has disclosed which specific drug-delivery technologies they plan to investigate first—options range from focused ultrasound and nanoparticle carriers to receptor-mediated transcytosis and viral vectors—nor have they revealed the size of the financial commitment. What is clear is the structure: the partnership intends to turn validated technologies into investable companies, which could accelerate the timeline from lab to clinical application.

The announcement drew attention from European startup watchers and reinforces a pattern of DSV's thesis-driven company creation: pick a high-impact bottleneck, assemble the right scientific and commercial capabilities, and build ventures to solve it.